| INTRODUCTION
Interferon-based therapy for hepatitis C (HCV) is contraindicated in patients with advanced cirrhosis because of poor tolerability and safety concerns. Until recently, the lack of a safe antiviral therapy to prevent disease progression in patients with severe HCV-induced liver injury meant that most eventually developed liver failure for which the only effective treatment was liver transplantation. Indeed decompensated cirrhosis due to chronic hepatitis C viral infection has become the commonest indication for liver transplantation. 1 However, recurrent HCV infection post-transplant is almost universal, often following an accelerated course with rapid progression to cirrhosis in the absence of treatment. 2, 3 Direct acting antivirals have greatly improved the results of HCV treatment. 4 Furthermore, a very low incidence of side effects has enabled the use of some classes of these drugs in patients with advanced liver disease who are poor candidates for interferon.
There is emerging evidence that treatment of patients with advanced HCV cirrhosis with regimens, which include the nucleoside inhibitor, sofosbuvir, in combination with an NS5A inhibitor is well tolerated and effective across multiple genotypes, although the reported SVR12 rates appear to be lower than in non-cirrhotic populations. [5] [6] [7] Recent findings suggest that successful antiviral therapy can improve liver function in patients with decompensated HCV cirrhosis. 5, [8] [9] [10] However, these studies have several limitations. First, the majority of patients included were Child-Pugh B with relatively low model for end-stage liver disease (MELD) scores. [6] [7] [8] [9] Second, patients with genotype 3 infection were not well represented. Third, in several studies the direct acting antiviral regimen was not uniform and of varying treatment duration and, finally, there is limited data regarding on treatment mortality and need for rescue liver transplantation.
In Australia, access to the direct acting antivirals outside of clinical trials was very limited until March 1, 2016 when access was given to most patients following funding of treatment under the Pharmaceutical Benefits Scheme. In the preceding 18 months, the only access to any form of direct acting antiviral therapy was through randomised controlled trials or compassionate use programs.
In the second quarter of 2014, an investigator-initiated, prospective, open-label study was commenced which provided access to sofosbuvir and daclatasvir therapy for patients with decompensated HCV cirrhosis with all genotypes including genotype 3. Treatment was provided only to patients who had MELD scores of 15 or greater and were therefore at significant risk of dying or requiring liver transplantation before government-funded drug therapy became available. The decision to treat all patients in the study with sofosbuvir and daclatasvir for 6 months was based on limited data at that time suggesting that these drugs have pan-genotypic efficacy and that 3 months combination therapy may not be sufficient in advanced cirrhosis. 11 Although clinicians were given the option of using ribavirin, this occurred in a minimal number of patients (n = 2) because of concern regarding its potential toxicity in advanced liver failure patients. 
| ENDPOINTS
The primary outcomes included (1) treatment completion; (2) SVR12 defined as sustained virologic response 12 weeks after completion of treatment and (3) liver related outcomes including death, transplantation and changes in MELD and Child-Pugh scores.
The study was approved by the institution review board and ethics committees at each clinical site prior to study commencement.
All patients provided written, informed consent prior to commencing the treatment. Over one-third of patients had failed previous HCV therapy (40%) and 23% of patients had a history of hepatocellular carcinoma (n = 25).
| STATISTICAL ANALYSIS
All 108 patients were treated with sofosbuvir and daclatasvir of whom two also received ribavirin. Seventy-eight of the 108 patients (72%) completed 24 weeks of treatment. The median (IQR) treatment duration in these patients was 168 (167-175) days. For all patients, the study outcomes are reported as at the 3-month followup post end of treatment.
| Safety
Thirty patients were unable to complete treatment and are discussed in more detail below. Of these, 27 underwent liver transplantation (n = 16) or died (n = 11) on treatment. The remaining three stopped treatment at physician discretion due to "failure to Unknown hepatitis C status (n = 1)
Hepatitis C PCR positive (n = 1) 
| Factors predicting SVR12 in those completing
treatment Tables 2 and 3 shows the factors analysed with respect to end of treatment response and SVR12. Given that the intervention of liver transplantation can affect SVR12 rates, the four patients who were transplanted post treatment but within the 12 week follow-up period were removed from the subsequent analysis of baseline factors associated with SVR12.
There was no statistically significant difference in SVR12 rates between genotypes (Fisher's exact test, P = .368). Per protocol, SVR12 in genotype 1 was achieved in 27 of 34 patients (79.1%), 24 of 35 genotype 3 patients (68.6%) and 100% of genotype 2 and genotype 4 (n = 2 and 3 respectively).
While serum alanine aminotransferase (ALT) at baseline was significantly associated with hepatitis C PCR negativity at the end of treatment, it was not associated with SVR12 or failure to complete treatment due to death or transplantation ( Figure 2 ) (Tables 2 and   3 ). There were no other statistically significant predictors of SVR12 identified using baseline characteristics (including MELD and ChildPugh score). Table 4 shows the changes in Child-Pugh score, MELD score and ALT. In the 73 patients who were hepatitis C PCR negative at end of treatment, there was a significant change noted in median (IQR) MELD score (À2 (À4 -À1), P = .000), median Child-Pugh score (À2 (À3 -À1) P = .000) and median ALT (À28 (À60 -À12), P = .000). The five patients whom failed to clear the hepatitis C at end of treatment had significant improvement in median Child-Pugh score À1 (À2 -À1) only (P = .04).
| Change in liver disease parameters
In the 56 patients who achieved SVR12, the improvements in liver parameters observed at end of treatment persisted at 12 weeks Results are expressed as median (IQR) unless otherwise specified.
post treatment (Table 5) . Relapse was not associated with significant deterioration in liver function. In those who relapsed, ALT increased from median 27.5 U/L to 57.5 U/L, while the median MELD decreased from 14 to 12.5 and median Child-Pugh score changed insignificantly from 8 to 9 (P = .88) between end of treatment and 12 weeks post treatment, respectively.
T A B L E 2 Per-protocol-analysis of patients completing 24-week treatment according to baseline characteristics (n = 78) there was an improvement in severity of ascites in both groups (SVR12 and hepatitis C relapse) regardless of hepatitis C clearance (Friedman test, P = .014). There was no difference in the degree of improvement between the groups (SVR12 versus relapse) (Fisher's exact test, P = 1.000).
Encephalopathy was present in 69% (n = 74) of patients at baseline (Table 1 ). In the 68 patients who were hepatitis C PCR negative at end of treatment and followed to 12 weeks post treatment (and not transplanted), encephalopathy had been recorded in 44 patients at baseline, of whom 30 patients were noted to have improved at the week 12 post-treatment assessment. However, this improvement did not reach statistical significance overall (Friedman test, P = .069) (Table 6 ). In the SVR12 group, improvement in encephalopathy trended towards significance (P = .051). Thirty-three patients had no change in encephalopathy severity documented, while five were noted to have worsening encephalopathy. There was no difference in the improvement between groups (SVR12 versus relapse) (Fisher's exact test, P = .238). (Table 7) . .080
| Deaths and transplantation
All results expressed as median (IQR). HCV, hepatitis C virus; PCR, polymerase chain reaction; ALT, alanine aminotransferase. P-values calculated using Wilcoxon matched pairs signed rank test. .0001 16 (15.5-18) 12.5 (11) (12) (13) (14) (15) (16) (17) .065
Baseline Child-Pugh SVR12 Child-Pugh 10 (9-11) 8 (6-9.5)
.0001 10 (9-11) 9 (7.5-9. Baseline platelet count, Child-Pugh score and MELD were found to significantly predict transplantation compared to those completing treatment and whom were not transplanted ( Table 8 ).
The only variable that remained significant on multivariable analysis was the MELD score. A MELD of 20 or more was highly predictive of transplantation, the odds ratio for MELD ≥ 20 being 13. 
| DISCUSSION
This paper reports the outcome of direct acting antiviral-based rescue therapy in a cohort of patients with severely decompensated hepatitis C-related cirrhosis. In the current study, all patients had MELD scores greater than 15, the majority of whom (64%) were patients with Child-Pugh C at baseline, with 82% percent having ascites and 69% with hepatic encephalopathy. Other studies investigating the outcomes of direct acting antiviral therapy in decompensated disease have included patients with relatively low MELD and
Child-Pugh scores compared to our cohort. In the SOLAR 1 and SOLAR 2 studies of sofosbuvir and ledipasvir with and without ribavirin, over 50% of patients were Child-Pugh B and in the Ally-1 study only 26% were Child-Pugh C, whilst 53% were Child-Pugh B. [6] [7] [8] In the UK-EAP study, 68% were Child-Pugh B and less than 10%
were Child-Pugh C with a median MELD of 11. 9 Likewise, the patients in Astral-4 had a median Child-Pugh score of B8 and MELD of 10 with 95% having MELD scores less than 15. 10 Thus this is the largest report of treatment outcomes in such a uniformly advanced group of patients, all of whom met criteria for liver transplantation.
This may explain the low SVR12 in our study of 70% compared to these other studies in decompensated patients, which report SVR12 rates of around 90% and is in keeping with the recent findings of Guarino et al, reporting overall mean SVR12 rates of 74.9% in their systematic review of Child-Pugh C patients. [6] [7] [8] [9] [10] 13, 14 The genotype 3 patients in our study are of particular interest (n = 47; 43.5%). In the group of 78 patients who completed treatment, that is, did not die and were not transplanted on treatment, 49% had genotype 3 infection. There is limited data on treatment outcomes for genotype 3 patients with decompensated liver disease.
In the SOLAR 1 and 2 studies, all patients had genotype 1 infection and Astral-4 consisted of only 15% genotype 3. The UK-EAP study had 41% genotype 3 patients' enrolled but less severe liver disease, as did the French cohort (100% genotype 3; only 15% Child-Pugh B/C classes) and ALLY-3 study patients (compensated cirrhosis with median albumin 43 g/L and platelet count of 161 9 10 9 /L). 14, 15 Thus, this is the first report of outcomes in genotype 3 infected patients with such severe liver disease. Previous studies have suggested that cirrhotic genotype 3 patients treated with direct acting antivirals have significantly lower SVR12 rates compared to genotype 1 infected patients. 9, 16 In the current study, although the rates were lower in the genotype 3 patients (68% on per-protocol-analysis) compared to those with genotype 1 (78%), this was not statistically significant. These results suggest that the low SVR12 rates in our study related to the presence of decompensated disease per se rather than any major difference in the response of different genotypes in advanced cirrhosis. Interestingly, the majority of treatment failures (66%) in those who completed treatment were related to relapse, suggesting that the failure to achieve SVR12 in these patients was not due to a primary failure to achieve suppression of viral replication in the advanced cirrhotic liver.
In the evaluation of factors predicting treatment failure, baseline
ALT was noted to be significantly higher in those patients who were hepatitis C PCR positive at the end of treatment compared to those who were hepatitis C PCR negative. In the study by Reddy et al, a positive predictor of SVR12 was albumin level, whilst negative predictors were found to be elevated bilirubin and genotype 1a. 17 Other studies have suggested that low platelet count and hypoalbuminaemia are associated with reduced SVR rates. In our cohort of very advanced cirrhotic patients, measures of diseases severity including platelet count, albumin, MELD and Child-Pugh score did not have predictive value (Table 3 ). This is probably because, in contrast to other studies, at baseline almost all patients had hypoalbuminaemia and thrombocytopaenia and all had MELD scores greater than or equal to 15.
It should be noted that all patients received a uniform and standardised treatment regimen of sofosbuvir and daclatasvir for 6 months and only two patients received the additional ribavirin. This compares to the SOLAR studies, in which sofosbuvir and ledipasvir was prescribed for 12 weeks all with ribavirin for genotype 1 patients. 6 In other studies including the French study, 21% of patients received sofosbuvir, daclatasvir and ribavirin for mostly 24 weeks (while 20% of the patients received sofosbuvir and daclatasvir without ribavirin for 12 weeks and 59% received 24 weeks). 15 The overall SVR12 rate was 89% (including non-cirrhotics). 15 We chose the pan-genotypic sofosbuvir and daclatasvir regimen primarily because of the prevalence of genotype 3 infection in the Australian community. 12 In addition, sofosbuvir and ledipasvir was not available to treat genotype 1 patients at that time. We chose a 6-month course of therapy because of the severity of the disease in the cohort and anticipated ribavirin would have been poorly tolerated in these patients. Whether SVR12
rates are altered by the addition of ribavirin to the various direct acting antiviral regimens in patients with advanced decompensated liver disease remains unknown. The results of the Ally 3+ study suggest that the addition of ribavirin improves SVR rates in compensated cirrhotic genotype 3 patients treated with sofosbuvir and daclatasvir for 12 weeks. 14 There did not appear to be a significant change in SVR12
with extension of this treatment to 16 weeks. In our cohort of decompensated patients, it is therefore possible that the addition of ribavirin to the 24-week sofosbuvir and daclatasvir regimen may have improved results in our patients.
In the patients who completed therapy, achievement of SVR12
was associated with significant improvement in MELD score, ChildPugh score and ALT as well as clinic parameters of liver disease including ascites severity. Overall, improvement in MELD occurred in two-thirds of the total patient group and this was consistent with other studies of direct acting antiviral treatment outcomes in hepatitis C patients with decompensated disease, although as a group the patients in our study had more severe disease. Approximately, a quarter of the 108 patients had no change or worsening of MELD scores.
There is limited data regarding the factors that predict mortality and transplant rates in patients with advanced decompensated disease who receive direct acting antiviral therapy. Not surprisingly, it was in the group of patients who did not improve on treatment, that deaths and transplants were most likely to occur (10 of 29 who did not improve versus 11 of 76 who did improve, P = .022). In our study, 10% of patients died and 19% were transplanted (with four transplants occurring post treatment due to lack of clinical improvement and physician discretion during the 12 week follow-up post end of treatment and despite having achieved negative end of treatment hepatitis C PCR (Figure 1) ). As would be expected in the patients who died, there was worsening of MELD scores (median of 16 to median of 23) from baseline to death (Table 7) . However, it was noteworthy that MELD scores at baseline did not predict mortality and were not significantly different from those patients who successfully completed the 24-week sofosbuvir and daclatasvir treatment. Moreover, there was an equal mortality rate in patients who had baseline MELD scores between 15 and 19 versus those with MELD scores greater than or equal to 20. Thus, in this group of patients with decompensated cirrhosis, deaths were due to a rapidly progressive liver failure that appeared to be largely unpredictable based on pre-treatment status. There was no significant change in
Child-Pugh score in these patients, which may be related to the significant increase in creatinine that was noticed in the patients imme- This study also raises the issue of whether to treat these patients pre-or post-transplant. The International Liver Transplantation Society guidelines suggest that treatment should be considered pre-transplantation in patients with MELD scores less than 20 whilst in those patients with baseline MELD scores greater than 30, treatment is recommended post-transplantation. 18 There is controversy regarding this middle cohort of patients. In the study by Belli and colleagues, after 60 weeks follow-up, one-third of patients were inactivated and 20% were delisted from transplantation post SVR12. 19 As discussed above, we also found a baseline above 20 was unlikely to lead to clinically significant improvement in patients treated pre-transplantation. Thus, given that there was low SVR12 in the decompensated cirrhotics with the current direct acting antiviral regimens, it may be reasonable to consider treatment post-transplantation in these difficult-to-treat patients. Longer term follow-up of these patients will allow us to make further conclusions regarding their outcome.
In conclusion, this paper provides new information on the response to direct acting antiviral therapy in patients with advanced decompensated disease meeting current criteria for liver transplantation. It emphasises the importance of treating cirrhotic patients earlier rather than at the decompensated stage with high MELD, whereby the SVR12 is lower, there is a higher rate of incomplete therapy (from death or rescue liver transplantation), lower tolerability to ribavirin, and also ongoing decompensation despite achieving SVR12. We have found SVR12 rates of 70%, which is significantly lower than the 95% consistently quoted in patients with compensated disease treated with sofosbuvir/NS5A inhibitor therapy.
Although the direct acting antiviral regimen used in this study is not the current choice of therapies in genotype 1 infection, we would argue that recent results with newer regimens such as sofosbuvir/ velpatasvir are not dissimilar to our data in Child-Pugh C patients.
The paper does not allow us to answer the question of whether to treat before or after transplant. Improvements in MELD scores are consistent with the literature and the SVR12 rates suggests that many patients (20%-30%) who are treated at a very late stage of disease will go to transplant with viraemia, which will require treatment post-transplant to prevent severe recurrent disease. This applies to all current regimens including sofosbuvir/ledipasvir, sofosbuvir/daclatasvir and sofosbuvir/velpatasvir. Emerging regimens will allow treatment of potential NS5a-resistant viruses in the post-transplant period. However, such regimens are not as yet freely available worldwide. Thus the timing and overall approaches to therapy in patients with advanced decompensated liver disease remains challenging.
